Reasanz

FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure Drug
Forbes
Thu, 03/27/14 - 04:58 pm
FDA
Novartis
serelaxin
acute heart failure
advisory panels
Reasanz